Bavdegalutamide

A nonsteroidal antiandrogen for prostate cancer treatment

Bavdegalutamide
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Bavdegalutamide is a nonsteroidal antiandrogen (NSAA) that is under investigation for the treatment of prostate cancer. It is designed to inhibit the action of androgens, which are male hormones that can promote the growth of cancer cells in the prostate.

Mechanism of Action

Bavdegalutamide functions by binding to the androgen receptor (AR) and inhibiting its activity. The androgen receptor is a type of nuclear receptor that is activated by binding to androgens, such as testosterone and dihydrotestosterone (DHT). By blocking this receptor, bavdegalutamide prevents androgens from stimulating the growth of prostate cancer cells.

Development and Clinical Trials

Bavdegalutamide is currently in the clinical trial phase of development. It is being studied for its efficacy and safety in patients with advanced prostate cancer, particularly those who have become resistant to other forms of hormone therapy. The drug is being evaluated in various phases of clinical trials to determine its optimal dosing, effectiveness, and potential side effects.

Pharmacokinetics

The pharmacokinetics of bavdegalutamide involve its absorption, distribution, metabolism, and excretion in the body. As a nonsteroidal compound, it is designed to have a favorable pharmacokinetic profile, allowing for effective inhibition of the androgen receptor with minimal side effects. The specific pharmacokinetic parameters are being studied in ongoing clinical trials.

Potential Side Effects

As with other nonsteroidal antiandrogens, bavdegalutamide may have side effects, although the specific profile is still under investigation. Common side effects of NSAAs can include fatigue, hot flashes, and gastrointestinal disturbances. The safety profile of bavdegalutamide will be better understood as clinical trials progress.

Related Pages

• Prostate cancer
• Androgen receptor
• Nonsteroidal antiandrogen
• Hormone therapy (oncology)